This approach is in the the media as a potential positive study in MS. You have asked me what I think. I haven’t seen the human sudy, and it is not supposed to have finished yet and they say the data is blinded. However, the animal study has just been reported. Have a read if you are interested.
Let’s have a look together
CNM-Au8 is a stable, aqueous (watery) suspension of gold (Au) nanoparticles (small particles) in the shape of hexagonal(6-sided) bi-pyramids (double pyramids), pentagonal (five-sided) bi-pyramids etc., octahedrons (see below)
Now they report that the gold augmented remyelination following feeding with cuprizone, which is an oligodendrocyte toxin.
However, looking at the data you can see the positive response is not uniform (green dots). Don’t you think that it is driven by some animals going very well (in boxes) and the majority doing not different from the vehicle. If it was put in the drinking water it did not work so enough had to be given orally. So if this optimized in an animal model. it suggests that if there is translatability, it is not going to work for every body.
There was more myelin produced….Can you see it. However, it looks like a statistical thing rather than something that passes the smack you in the eye test.
Then another model was used with a myelin toxin. They say there was a 43% increase and then they P=0.15, so this means there was no treatment effect.
Then we get the cell culture work and it looks like it is doing something, but there is no real dose-response and then we get the heat map and it is clear cut doing something, but the treatment effect was not so convincing and we ask what is the reality
Nanocatalytic activity of clean-surfaced, faceted nanocrystalline gold enhances remyelination in animal models of multiple sclerosis. Robinson AP, Zhang JZ, Titus HE, Karl M, Merzliakov M, Dorfman AR, Karlik S, Stewart MG, Watt RK, Facer BD, Facer JD, Christian ND, Ho KS, Hotchkin MT, Mortenson MG, Miller RH, Miller SD. Sci Rep. 2020 Feb 11;10(1):1936.
Development of pharmacotherapies that promote remyelination is a high priority for multiple sclerosis (MS), due to their potential for neuroprotection and restoration of function through repair of demyelinated lesions. A novel preparation of clean-surfaced, faceted gold nanocrystals demonstrated robust remyelinating activity in response to demyelinating agents in both chronic cuprizone and acute lysolecithin rodent animal models. Furthermore, oral delivery of gold nanocrystals improved motor functions of cuprizone-treated mice in both open field and kinematic gait studies. Gold nanocrystal treatment of oligodendrocyte precursor cells in culture resulted in oligodendrocyte maturation and expression of myelin differentiation markers. Additional in vitro data demonstrated that these gold nanocrystals act via a novel energy metabolism pathway involving the enhancement of key indicators of aerobic glycolysis (breaking down glucose in the presence of oxygen). In response to gold nanocrystals, co-cultured central nervous system cells exhibited elevated levels of the redox coenzyme nicotine adenine dinucleotide (NAD+), elevated total intracellular ATP levels, and elevated extracellular lactate levels, along with upregulation of myelin-synthesis related genes, collectively resulting in functional myelin generation. Based on these preclinical studies, clean-surfaced, faceted gold nanocrystals represent a novel remyelinating therapeutic for multiple sclerosis.